SMALL-CAP WINNERS & LOSERS: LMS Capital rises on capital return plan
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday. Read More
Price | 352.00p on 11-07-2025 | at 18:05:10
---|---|
Change | -1.00p -0.28% |
Buy | 363.00p |
Sell | 351.50p |
Buy / Sell OXB Shares |
Last Trade: | Unknown 36,237.00 at 352.00p |
Day's Volume: | 200,808 |
Last Close: | 352.00p |
Open: | 353.50p |
ISIN: | GB00BDFBVT43 |
Day's Range | 349.50p - 365.00p |
52wk Range: | 232.50p - 455.00p |
Market Capitalisation: | £374m |
VWAP: | 356.54223p |
Shares in Issue: | 106m |
Oxford Biomedica (OXB) Latest Trades |
||||
Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
---|---|---|---|---|
Unknown* | 36,237 | 352.00p | Uncrossing Trade |
16:35:23 - 11-Jul-25 |
Buy* | 1,402 | 353.63p | Ordinary |
16:26:45 - 11-Jul-25 |
Buy* | 56 | 354.00p | Automatic Execution |
16:19:48 - 11-Jul-25 |
Buy* | 190 | 352.50p | Automatic Execution |
16:17:23 - 11-Jul-25 |
Buy* | 250 | 352.50p | Automatic Execution |
16:17:23 - 11-Jul-25 |
Buy* | 265 | 352.50p | Automatic Execution |
16:17:23 - 11-Jul-25 |
Buy* | 1,000 | 352.325p | Ordinary |
16:13:00 - 11-Jul-25 |
Buy* | 100 | 351.00p | Automatic Execution |
16:02:58 - 11-Jul-25 |
Buy* | 42 | 350.50p | Automatic Execution |
16:02:58 - 11-Jul-25 |
Buy* | 31 | 350.50p | Automatic Execution |
16:02:58 - 11-Jul-25 |
Oxford Biomedica (OXB) Regulatory News |
||
Date | Source | Headline |
---|---|---|
2nd Jul 2025 7:00 am | RNS | Director Declaration |
1st Jul 2025 7:00 am | RNS | Block listing Interim Review |
1st Jul 2025 7:00 am | RNS | Total Voting Rights |
23rd Jun 2025 7:00 am | RNS | OXB completes acquisition of US subsidiary |
17th Jun 2025 6:00 pm | RNS | Director/PDMR Shareholding |
11th Jun 2025 6:02 pm | RNS | Result of Annual General Meeting |
11th Jun 2025 7:02 am | RNS | AGM Update |
10th Jun 2025 10:49 am | RNS | Holding(s) in Company |
5th Jun 2025 7:00 am | RNS | Block Listing Application |
3rd Jun 2025 7:00 am | RNS-R | OXB Launches Advisory Board |